MINDCURE has released the initial version of its iSTRYM digital therapeutics platform and expects to begin full commercial deployment in Q1 of 2022.
Mind Cure Health Inc
Company:
Mind Cure Health Inc
Symbol:
MCUR
Country:
Canada
Sector:
Life Sciences
Industry:
psychedelic drugs
Established:
2020
Website:
Company:
Mind Cure Health Inc
Symbol:
MCUR
Country:
Canada
Sector:
Life Sciences
Industry:
psychedelic drugs
Established:
2020
Website:
Company Brief
Mind Cure Health Inc (CAN:MCUR / US:MCURF) is a life sciences company focusing on opportunities in psychedelic drug development and mental health services. Mind Cure’s quest is to treat the profound distress of a world suffering from a Mental Health Crisis.
Mind Cure’s founding team and advisors have deep industry-specific experience in biotech, life sciences, new product discovery, research, technology, and entrepreneurship. The company is uniquely situated in Canada, benefiting from a sophisticated investment community, world-class scientific professionals, and government leadership in research.
Mind Cure’s founding team and advisors have deep industry-specific experience in biotech, life sciences, new product discovery, research, technology, and entrepreneurship. The company is uniquely situated in Canada, benefiting from a sophisticated investment community, world-class scientific professionals, and government leadership in research.
52-Week Range:
CAD$0.20 - $1.09
Current Outstanding:
53,422,596
Warrants:
9,139,404
Options:
7.205,000
Fully Diluted:
69,767,000
Market Cap:
CAD$48.6 million
52-Week Range:
CAD$0.20 - $1.09
Current Outstanding:
53,422,596
Warrants:
9,139,404
Options:
7.205,000
Fully Diluted:
69,767,000
Market Cap:
CAD$48.6 million
Highlights
- Led by Kelsey Ramsden, twice Canada’s Top Female Entrepreneur, and the first female CEO of a public psychedelic drug company
- A wealth of psychedelic drug expertise/experience among MCUR’s team of Advisors, including Hamilton Morris and Dr. Dan Engle
- Will be opening first psychedelic-assisted mental health therapy clinic in May 2021, offering both ketamine- and psilocybin-assisted therapy
- Recent acquisition of a digital therapeutics platform will enhance and streamline clinic operations
- Initial focus of psychedelic drug R&D is on ketamine-, psilocybin- and ibogaine-derived compounds
Related Articles
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE's proprietary ibogaine manufacturing has reached the second stage of development: assessing the quality of its synthetic ibogaine.
TSI EDITOR |
2021-07-27
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
TSI EDITOR |
2021-05-20
The NEXT Psychedelic Stock To Uplist On The NASDAQ?
MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second...???
TSI EDITOR |
2021-04-30
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
MINDCURE updates investors on key elements of its business model, including its iSTRYM digital therapeutics platform and its emerging TBI research.
TSI EDITOR |
2021-04-29
Second-Chance Buying Opportunity With Psychedelic Stock Warrants
In 2020, investors were able to reap spectacular returns from psychedelic stock warrants. With a new rally starting in the sector, a there is a NEW opportunity in these warrants.
TSI EDITOR |
2021-04-27
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now